WASHINGTON, D.C. - The U.S. solicitor general on Feb. 25 urged the U.S. Supreme Court to not decide, for now, the pleading requirements for a False Claims Act lawsuit alleging that a company engaged in off-label marketing of a drug (United States, ex rel. Noah Nathan v. Takeda Pharmaceuticals North America, Inc., et al., No. 12-1349, U.S. Sup.).